We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+48.42%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$261M
AUM Growth
+$69.2M
Cap. Flow
+$1.22M
Cap. Flow %
0.47%
Top 10 Hldgs %
97.6%
Holding
13
New
–
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ZSAN
Zosano Pharma Corporation
ZSAN
+$1.22M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$134M 51.51%
3,835,722
– –
EIDX
2
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$64.5M 24.71%
1,123,630
– –
TECX
3
Tectonic Therapeutic
TECX
$529M
$18M 6.89%
74,423
– –
SYRE icon
4
Spyre Therapeutics
SYRE
$8.54B
$9.86M 3.78%
51,646
– –
BCEL
5
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$6M 2.3%
387,653
– –
MRKR icon
6
Marker Therapeutics
MRKR
$18.8M
$5.76M 2.21%
200,000
– –
OBSV
7
DELISTED
ObsEva SA Ordinary Shares
OBSV
$5.3M 2.03%
1,386,338
– –
ZSAN
8
DELISTED
Zosano Pharma Corporation
ZSAN
$4.13M 1.58%
77,664
+19,705
+34% +$1.22M
VIRX
9
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.41M 1.31%
288,571
– –
RCUS icon
10
Arcus Biosciences
RCUS
$3.55B
$3.37M 1.29%
333,333
– –
VRNA
11
DELISTED
Verona Pharma
VRNA
$2.55M 0.98%
443,596
– –
NBRV
12
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.52M 0.97%
7,641
– –
ACRS icon
13
Aclaris Therapeutics
ACRS
$726M
$1.2M 0.46%
634,455
– –

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Aisling Capital Management held 13 positions worth $261M, up 36% from $192M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Trading was light in Q4 2019: portfolio turnover was 0%. Aisling Capital Management opened no new positions and made no exits, leaving the 13-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management added most to Zosano Pharma Corporation in Q4 2019, an estimated $1.22M increase.
  • Aisling Capital Management's ten largest holdings make up 98% of its $261M portfolio in Q4 2019.
  • Aisling Capital Management opened 0 new positions and closed 0 in Q4 2019.
  • Aisling Capital Management's portfolio value rose 36% quarter-over-quarter to $261M.

Based on Aisling Capital Management's 13F filing for Q4 2019, filed 6 Feb 2020.